Dr Patel on the Exploration of Sacituzumab Govitecan in NSCLC
December 20th 2023Sandip P. Patel, MD, discusses the utilization of sacituzumab govitecan in non–small cell lung cancer, highlighting trials in which the TROP2-directed antibody-drug conjugate is being evaluated in this patient population.
Read More
Dr Patel on Establishing a Consensus for Lung Cancer Treatment
October 12th 2023Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting the similarities and differences between treating lung cancer in community oncology settings vs academic medical center settings.
Read More
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC
November 25th 2020Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.
Read More
Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC
May 24th 2018Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).
Read More